| Literature DB >> 25785585 |
Chundan Bao1, Dianfeng Zhang2, Bo Sun3, Li Lan3, Wenxiu Cui3, Guohua Xu3, Conglan Sui3, Yibaina Wang1, Yashuang Zhao1, Jian Wang3, Hongyuan Li1.
Abstract
To identify optimal cut-off points of fasting plasma glucose (FPG) for two-step strategy in screening abnormal glucose metabolism and estimating prevalence in general Chinese population. A population-based cross-sectional study was conducted on 7913 people aged 20 to 74 years in Harbin. Diabetes and pre-diabetes were determined by fasting and 2 hour post-load glucose from the oral glucose tolerance test in all participants. Screening potential of FPG, cost per case identified by two-step strategy, and optimal FPG cut-off points were described. The prevalence of diabetes was 12.7%, of which 65.2% was undiagnosed. Twelve percent or 9.0% of participants were diagnosed with pre-diabetes using 2003 ADA criteria or 1999 WHO criteria, respectively. The optimal FPG cut-off points for two-step strategy were 5.6 mmol/l for previously undiagnosed diabetes (area under the receiver-operating characteristic curve of FPG 0.93; sensitivity 82.0%; cost per case identified by two-step strategy ¥261), 5.3 mmol/l for both diabetes and pre-diabetes or pre-diabetes alone using 2003 ADA criteria (0.89 or 0.85; 72.4% or 62.9%; ¥110 or ¥258), 5.0 mmol/l for pre-diabetes using 1999 WHO criteria (0.78; 66.8%; ¥399), and 4.9 mmol/l for IGT alone (0.74; 62.2%; ¥502). Using the two-step strategy, the underestimates of prevalence reduced to nearly 38% for pre-diabetes or 18.7% for undiagnosed diabetes, respectively. Approximately a quarter of the general population in Harbin was in hyperglycemic condition. Using optimal FPG cut-off points for two-step strategy in Chinese population may be more effective and less costly for reducing the missed diagnosis of hyperglycemic condition.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25785585 PMCID: PMC4364753 DOI: 10.1371/journal.pone.0119510
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
AUCs and screening potential for FPG alone in screening undiagnosed diabetes and/or pre-diabetes with optimal cut-off points.
| Optimal cut-off point (mmol/l) | Positive/Negative | Sensitivity (%) | Specificity (%) | Likelihood ratio (%) | Predictive value (%) | Kappa | AUC (95% CI) | Post-test probability (%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Positive | Negative | Positive | Negative | Men | Age >40 years | Obesity | Abdominal obesity | ||||||
| > = 5.6 for undiagnosed diabetes | 696/6768 | 82.0 | 91.6 | 9.8 | 0.2 | 50.2 | 98.0 | 0.57 | 0.93(0.92–0.94) | 50.4 | 55.0 | 56.3 | 57.2 |
| > = 5.3 for diabetes and pre-diabetes | 1728/5736 | 72.4 | 94.4 | 12.8 | 0.3 | 79.4 | 91.9 | 0.69 | 0.89(0.88–0.90) | 78.6 | 82.5 | 83.3 | 83.2 |
| > = 5.3 for diabetes and pre-diabetes | 1478/5986 | 68.0 | 90.2 | 6.9 | 0.4 | 63.0 | 91.9 | 0.57 | 0.86(0.84–0.87) | 61.3 | 67.5 | 68.9 | 68.2 |
| > = 5.3 for pre-diabetes | 1032/5736 | 62.9 | 94.1 | 10.6 | 0.4 | 65.7 | 93.4 | 0.58 | 0.85(0.83–0.87) | 61.1 | 66.5 | 67.5 | 66.7 |
| > = 5.0 for pre-diabetes | 782/5986 | 66.8 | 75.8 | 2.8 | 0.4 | 26.5 | 94.6 | 0.28 | 0.78(0.76–0.80) | 22.3 | 27.6 | 28.9 | 27.1 |
| > = 4.9 for IGT | 674/6094 | 62.2 | 73.8 | 2.4 | 0.5 | 20.8 | 94.6 | 0.19 | 0.74(0.73–0.75) | 17.3 | 22.0 | 23.2 | 21.2 |
AUCs, the area under the receiver-operating characteristic curves; FPG, fasting plasma glucose.
*Number of participants based on golden standard. Pre-diabetes includes IFG and/or IGT.
†IFG using ADA criteria, FPG 5.6 to <7.0 mmol/l;
‡IFG using WHO criteria, FPG 6.1 to <7.0 mmol/l; IGT, 2-h PG 7.8 to <11.1 mmol/l.
§ P <0.001 compared with area under curve of 2 hour post-load plasma glucose.
Fig 1The total cost per case identified by two-step strategy at different FPG cut-points for further OGTT test.
In Fig.1A, further OGTT was not conducted for subjects with FPG ≥5.6 mmol/l (≥6.1mmol/l) in the case of screening for both diabetes and pre-diabetes using ADA criteria (WHO criteria). In Fig.1B and 1C, further OGTT was not conducted for subjects with FPG ≥7.0 mmol/l in the case of screening for undiagnosed diabetes or both diabetes and pre-diabetes or pre-diabetes alone or IGT.
Positive likelihood ratios of different FPG cut-off points.
| FPG (mmol/l) | Number of participants based on 2-h PG (mmol/l) | Positive likelihood ratios | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Total | <7.8 | > = 7.8 and <11.1 | > = 11.1 | Diabetes | Diabetes and pre-diabetes | Diabetes and pre-diabetes | Pre-diabetes | Pre-diabetes | |
| <4.5 | 3237 | 3072 | 138 | 27 | 0.1 | 0.2 | 0.2 | 0.2 | 0.3 |
| 4.5–4.8 | 1637 | 1480 | 126 | 31 | 0.2 | 0.4 | 0.4 | 0.5 | 0.7 |
| 4.9–5.1 | 824 | 702 | 95 | 27 | 0.3 | 0.6 | 0.7 | 0.8 | 1.0 |
| 5.2–5.4 | 517 | 390 | 95 | 32 | 0.6 | 1.1 | 1.3 | 1.4 | 1.9 |
| 5.5 | 128 | 92 | 25 | 11 | 0.9 | 1.3 | 1.6 | 1.5 | 2.1 |
| 5.6–6.0 | 406 | 250 | 99 | 57 | 1.6 | - | 2.5 | - | 3.0 |
| 6.1–6.9 | 301 | 108 | 96 | 97 | 4.6 | - | - | - | - |
| 7.0- | 414 | 57 | 40 | 317 | - | - | - | - | - |
| Total | 7464 | 6151 | 714 | 599 | - | - | - | - | - |
FPG, fasting plasma glucose; 2-h PG, 2 hour post-load plasma glucose; Pre-diabetes includes IFG and/or IGT.
*IFG using ADA criteria, FPG 5.6 to <7.0 mmol/l;
†IFG using WHO criteria, FPG 6.1 to <7.0 mmol/l; IGT, 2-h PG 7.8 to <11.1 mmol/l.
Classification of FPG alone and 2-h PG alone for abnormal glucose metabolism in urban Harbin of China, 2008 (%, 95% CI).
| Diagnosis based on FPG | Diagnosis based on 2-h PG | Distribution across 2-h PG categories by FPG diagnostic category | Distribution across FPG and 2-h PG categories | ||
|---|---|---|---|---|---|
| ADA criteria | WHO criteria | ADA criteria | WHO criteria | ||
| Undiagnosed diabetes | Undiagnosed diabetes | 78.3(72.1–84.5) | 78.3(72.1–84.5) | 3.9(2.7–5.1) | 3.9(2.7–5.1) |
| IGT | 8.5(4.2–12.8) | 8.5(4.2–12.8) | 0.4(0.2–0.6) | 0.4(0.2–0.6) | |
| Normal | 13.2(10.0–16.4) | 13.2(10.0–16.4) | 0.7(0.5–0.9) | 0.7(0.5–0.9) | |
| IFG | Undiagnosed diabetes | 21.8(15.5–28.0) | 32.4(22.3–42.4) | 1.7(1.1–2.4) | 1.1(0.7–1.4) |
| IGT | 26.6(21.5–31.6) | 31.0(20.4–41.5) | 2.1(1.4–2.9) | 1.0(0.4–1.6) | |
| Normal | 51.6(44.0–59.4) | 36.6(28.9–44.3) | 4.2(2.7–5.7) | 1.2(0.7–1.7) | |
| Normal | Undiagnosed diabetes | 1.9(1.5–2.3) | 2.6(2.0–3.2) | 1.6(1.2–1.9) | 2.2(1.7–2.8) |
| IGT | 6.9(5.3–8.5) | 7.8(6.2–9.4) | 5.7(4.5–6.8) | 6.8(5.6–8.1) | |
| Normal | 91.2(89.5–92.9) | 89.6(87.6–91.6) | 75.2(70.2–80.2) | 78.3(73.9–82.5) | |
| Diagnosed diabetes | - | - | 4.4(2.8–6.0) | 4.4(2.8–6.0) | |
| Total | - | - | 100.0 | 100.0 | |
FPG, fasting plasma glucose; 2-h PG, 2 hour post-load plasma glucose; diagnosed diabetes, determined by self-report on interview.
*IFG using ADA criteria, FPG 5.6 to <7.0 mmol/l;
†IFG using WHO criteria, FPG 6.1 to <7.0 mmol/l; IGT, 2-h PG 7.8 to <11.1 mmol/l.